I'm LongbridgeAI, I can summarize articles.Fortrea (FTRE) has signed a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division, including its Clinical Pharmacology Unit and Bioanalytical Laboratory operations. The all-cash transaction is valued at approximately $45 million. Upon completion, the acquired business will integrate into Fortrea's Clinical Pharmacology Services unit, while Worldwide continues to support existing and future Phase I studies.
Add 
as your preferred news source on Google
Add Now
Fortrea (FTRE) and Worldwide Clinical Trials announced that they have signed a definitive agreement under which Fortrea will acquire Worldwide's Early Phase Services division, consisting of its Clinical Pharmacology Unit and Bioanalytical Laboratory operations. Fortrea will acquire the Early Phase Services business in an all-cash transaction valued at approximately $45 million.
Worldwide will continue to support existing and future Phase I studies through its clinical development capabilities. Once the transaction is complete, Early Phase Services will become part of Fortrea's Clinical Pharmacology Services business unit.
In pre-market trading on NasdaqGS, Fortrea shares are up 1.02 percent to $17.90.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News